Shots: The P-III EMPLULSE study (NCT04157751) will evaluate clinical benefits safety and tolerability of Jardiance (empagliflozin, 10mg, PO) in ~500 patients hospitalized for acute heart failure who have been stabilized […]readmore
Tags : Boehringer Ingelheim
1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell […]readmore
Shots: The global companies modernize their alliance as of Jan 01, 2020 to completely focus their expertise and investment on the development and commercialization of Jardiance (empagliflozin) for T2D, HF […]readmore
1. Medtronic Reports MHLW’s Shonin Approval and Launches Valiant Navion Thoracic Stent Graft System in Japan Published: Oct 31, 2019 | Tags: Medtronic, Reports, MHLW, Shonin Approval, Launches, Valiant Navion Thoracic […]readmore
Shots: The Defeat-NCD Partnership and BI partnered to address the access to healthcare issues related to NCDs by helping governments to strengthen national institutions, scaling up community-based health services and […]readmore
OraSure Technologies’ Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens Published: Oct 10, 2019 | Tags: Diagnostic, Oraquick Ebola Rapid […]readmore
Shots: The BT designation is based on P-III INBUILD study results assessing OFEV vs PBO in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression for 52 […]readmore
Shots: The P-III INBUILD trial involves assessing of OFEV vs PBO in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression for 52 wks. P-III INBUILD study […]readmore
1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. […]readmore
Shots: Inflammasome to receive up to $160M up front, R&D milestone, commercialization milestone with royalties on sales of the developed product. The companies will co-develop up to three therapies for […]readmore